Ticagrelor for the treatment of acute coronary syndromes

grafting than prasugrel plus aspirin. The risk of major bleeding not related to CABG did not differ between patients taking prasugrel and those taking ticagrelor. 3.7 The PLATO trial included a pre-specified sub-study of health economics and quality of life that evaluated the health-related quality of life for ticagrelor plus aspirin compared with clopidogrel plus aspirin. Investigators administered the EuroQual 5D (EQ-5D) questionnaire to 8,840 patients at discharge from hospital for the index ACS event, again at 6 months, and at the end of treatment in all countries where a version of EQ-5D in the country's official language was available. No differences in any of the items on the EQ-5D were found between the ticagrelor plus aspirin group and the clopidogrel plus aspirin group. Cost effectiveness 3.8 The manufacturer did not identify any publications that evaluated the cost effectiveness of ticagrelor for the treatment of ACS. The manufacturer developed a new economic model, informed by 9 existing economic evaluations. For the health economics evaluation of ticagrelor plus aspirin compared with prasugrel plus aspirin, the manufacturer presented the results of a published indirect comparison of the TRITON-TIMI 38 trial and the PLATO trial, conducted by an independent group. 3.9 The manufacturer
